Plasma-reduction for Apheresis Granulocyte transfusions in pediatric patients

Transfus Apher Sci. 2024 Apr;63(2):103879. doi: 10.1016/j.transci.2024.103879. Epub 2024 Jan 26.

Abstract

Granulocyte transfusion (GT) may be used to treat and prevent infections in patients with severe neutropenia or nonfunctioning granulocytes. For pediatric patients, the volume of granulocyte unit transfused is a crucial consideration given smaller blood volume and increased risk of volume overload compared to adults. There is limited literature on the optimal dosing or the maximum amount of granulocytes that can be tolerated, especially in pediatric patients. Additionally, no consensus exists regarding granulocyte collection method, frequency, or timing of GT initiation. Previous studies have described splitting or limiting collection volume for GT in pediatric patients, but these methods yield lower absolute neutrophil count (ANC) increment. Our blood supplier provides high-volume (0.5-1 L/unit), high-dose apheresis-collected granulocytes from donors stimulated with both granulocyte colony-stimulating factor and steroids. Here, we report cases of two pediatric patients with active infection undergoing bone marrow transplant with dramatic ANC increments (median one-hour ANC increment 5524/µL, interquartile range (IQR) 4417-10087; median 24-hour ANC increment 3880/µL, IQR 2550-5263) after infusing 100 mL plasma-reduced, apheresis collected GT. Our cases indicate that pediatric patients can tolerate 4-6 × 109/kg plasma-reduced GT and have detectable ANC with GT every 3 days.

Keywords: Apheresis-collected; Dosing; Granulocyte transfusion; Pediatric transfusion; Plasma-reduced.

MeSH terms

  • Adult
  • Blood Component Removal*
  • Blood Donors
  • Child
  • Granulocyte Colony-Stimulating Factor / therapeutic use
  • Granulocytes*
  • Humans
  • Leukocyte Transfusion
  • Neutrophils

Substances

  • Granulocyte Colony-Stimulating Factor